Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder

Abstract

The aim of the study was to verify the efficacy of vulvar Visnadine spray in premenopausal women affected by female sexual arousal disorder (FSAD). Thirty-eight women aged 25-40 years affected by FSAD were enrolled in the randomized crossover study, by two possible sequences: on-demand, washout, daily (A sequence); and daily, washout, on-demand (B sequence). The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess sexual function and sexual distress, respectively. Color Doppler ultrasonography was used to measure clitoral blood flow. The study had two follow-ups at 30 (T1) and 60 days (T2). Thirty-one women completed the study. Mean (SD) sexual activity and vulvar Visnadine spray usage was 1 ± 0.9 weekly during on-demand administration for both the sequences (Vs T0, p = NS). The mean sexual activity during daily usage was 2 ± 0.9 (Vs T0, p < .004) and 2 ± 0.8 (Vs T0, p < .001) for A and B sequences, respectively. FSFI total score, particularly genital arousal, improved more during the daily than during on-demand phases of both sequences (p < .001). Finally, clitoral blood flow improved significantly during daily usage of both the sequences (p < .001). Our study suggests that vulvar Visnadine spray could improve sexual performance of women affected by FSAD, producing changes in subjective and objective sexual aspects.

The Use of Natural Products for the Treatment of Female Sexual Dysfunction: A Systematic Review of Randomized Clinical Trials

“…Both spray and oil produced differences in the FSFI score with respect to placebo [15] [21], although the oil intervention was a pilot study. The other study found results to indicate the efficacy of both daily and on-demand use in women with HSDD [20].…”

“…Visasdine is a local treatment applied to the vulvar area 10 min before sexual stimulation. The 3 Visadine interventions are applied in different ways: One of them evaluated the use of spray on demand [15], another evaluated both on demand and daily use, without placebo group [20], whilst a further study assessed the use of Visnadine oil [21]. Both spray and oil produced differences in the FSFI score with respect to placebo [15] [21], although the oil intervention was a pilot study.…”

Female Sexual Dysfunctions: A Clinical Perspective on HSDD, FAD, PGAD, and FOD

“…Several promising data are also available for visnadine, a principle extracted from the plant Ammi Visnaga, capable of inhibiting smooth muscle contractile responses mediated by calcium entry. A 1% visnadine vulvar spray seems to improve sexual performance in women with arousal disorders [88]. Regarding systemic vasodilators, the evidence is less convincing, with meta-analytic data showing an overall improvement in sexual function compared to that with a placebo, but with some studies have reported negative findings [89].…”

Genitourinary Syndrome of Menopause: Epidemiology, Physiopathology, Clinical Manifestation and Diagnostic

“…Another new proposal includes the use of Visnadine, an active ingredient of the fruit of Ammi visnaga. The latter demonstrates potent vasodilatory activity and has ameliorated female sexual arousal disorder ( 51 ). Associated a Visnadine, prenylflavonoids, and phytoestrogens have been considered due to their potential role as estrogen receptor alpha selective agonist and may counteract the effects of postmenopausal estrogen loss.…”